However, key challenges remain: (1) many non-melanoma cancers have insufficient tyrosinase to activate certain prodrugs; (2) extracellular depletion can be bypassed by intracellular synthesis of amino acids; and (3) achieving efficient intracellular delivery while minimizing off-target effects is difficult for conventional targeting approaches. Here, TYR is linked to melanoma.